Employing Effective Multidisciplinary Care to Reduce the Burden of Myelodysplastic Syndrome 

Ryan Haumschild, PharmD, MS, MBA, CPEL, opens the discussion by defining the MDS disease state.

An expert perspective on the variety of MDS subtypes is provided.

Key opinion leaders discuss how patient quality of life is impacted by MDS treatment-associated challenges.

Financial considerations in MDS treatment are discussed.

Dr Haumschild leads a discussion surrounding the latest advancements in treatment algorithms for myelodysplastic syndrome.

Considerations for growth factor and stem cell transplant for patients with MDS is discussed.

A panel of experts discusses how novel agents are impacting the treatment landscape for patients diagnosed with MDS.

Treatment compliance impacted by oral versus IV therapy is evaluated.

Key opinion leaders discuss the process of adapting MDS treatment strategies for optimal impact of care.

Novel therapies in MDS treatment are evaluated by a panel of experts led by Dr Haumschild.

Experts discuss how collaborative care drives optimal MDS treatment.

The panelists highlight key takeaways for payors involved in MDS treatment.

Potential issues associated with insurance coverage and ways to navigate these challenges are discussed by medical experts.

The panelists provide their final takeaways from the discussion surrounding treatment of MDS.